TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.89 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2024-02-27
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-06-30 was $1.18M, a 2.16% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-03-31 was -$926.00K, a 388.47% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-12-31 was $1.38M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-09-30 was -$864.00K, a 173.59% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.89M, a 300.69% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $721.00K, a 64.71% decline from fiscal 2021.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2021 was $2.04M, a 17.09% decline from fiscal 2020.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2020 was $2.46M, a 13588.89% increase from fiscal 2019.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2023-12-31 | $2.89M 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $721.00K 10-K · filed 2024-02-27 | |||
| 2022-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $254.00K 10-Q · filed 2022-08-11 | $1.63M derived: sum of 3 quarters · filed 2023-03-17 | $770.00K derived: sum of 4 quarters · filed 2023-03-17 |
| 2022-03-31 | -$926.00K 10-Q · filed 2022-05-11 | $454.00K derived: sum of 2 quarters · filed 2023-03-17 | -$410.00K derived: sum of 3 quarters · filed 2023-03-17 | $796.00K derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $516.00K derived: sum of 2 quarters · filed 2023-03-17 | $1.72M derived: sum of 3 quarters · filed 2023-03-17 | $2.04M 10-K · filed 2023-03-17 |
| 2021-09-30 | -$864.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $342.00K derived: sum of 2 quarters · filed 2022-08-11 | $663.00K 10-Q · filed 2021-11-10 | $427.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.53M 10-Q · filed 2022-08-11 | $1.29M derived: sum of 3 quarters · filed 2022-08-11 | $2.46M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $321.00K 10-Q · filed 2022-05-11 | $85.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.26M derived: sum of 3 quarters · filed 2022-05-11 | $2.56M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $938.00K derived: sum of 2 quarters · filed 2022-03-14 | $2.24M derived: sum of 3 quarters · filed 2022-03-14 | $2.46M 10-K · filed 2022-03-14 |
| 2020-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.48M derived: sum of 2 quarters · filed 2021-11-10 | $2.70M 10-Q · filed 2021-11-10 | $2.72M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.53M 10-Q · filed 2021-08-05 | $1.54M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $222.00K 10-Q · filed 2021-05-11 | $239.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $18.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $1.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |